Paul Yonga

Dr. Paul Yonga

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Indian Journal of Medical Research
Verified
Journal Article
Open access
KAKamran Abbasi
Kamran Abbasi
PAParveen Ali
Parveen Ali
VBVirginia Barbour
Virginia Barbour
TBThomas Benfield
Thomas Benfield
KBKirsten Bibbins-Domingo
Kirsten Bibbins-Domingo
CZChris Zielinski
Chris Zielinski

2 July 2025 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
AAAbdulaziz Alhazmi
Abdulaziz Alhazmi
AKABRAHAM KATIME
ABRAHAM KATIME
AHAhneez Abdul Hameed
Ahneez Abdul Hameed
AMAlejandra Morales
Alejandra Morales
ESEsgitm Slamvi
Esgitm Slamvi

31 January 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
LDLouise O Downs
Louise O Downs
CCCori Campbell
Cori Campbell
PYPaul Yonga
Paul Yonga
GGGeorge Githinji
George Githinji
MAM Azim Ansari
M Azim Ansari
AEAnthony O Etyang
Anthony O Etyang
The aim of this systematic review and meta-analysis is to evaluate available prevalence and viral sequencing data representing chronic hepatitis B (CHB) infection in Kenya. More than 20% of the global disease burden from CHB is in Africa, however there is minimal high quality seroprevalence data from individual countries and little viral sequencing data available to represent the continent. We undertook a systematic review of the prevalence and genetic data available for hepatitis B virus (HBV) in Kenya using the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) 2020 checklist. We identified 23 studies reporting HBV prevalence and 8 studies that included HBV genetic data published in English between January 2000 and December 2021. We assessed study quality using the Joanna Briggs Institute critical appraisal checklist. Due to study heterogeneity, we divided the studies to represent low, moderate, high and very high-risk for HBV infection, identifying 8, 7, 5 and 3 studies in these groups, respectively. We calculated pooled HBV prevalence within each group and evaluated available sequencing data. Pooled HBV prevalence was 3.4% (95% CI 2.7–4.2%), 6.1% (95% CI 5.1–7.4%), 6.2% (95% CI 4.64–8.2) and 29.2% (95% CI 12.2–55.1), respectively. Study quality was overall low; only three studies detailed sample size calculation and 17/23 studies were cross sectional. Eight studies included genetic information on HBV, with two undertaking whole genome sequencing. Genotype A accounted for 92% of infections. Other genotypes included genotype D (6%), D/E recombinants (1%) or mixed populations (1%). Drug resistance mutations were reported by two studies. There is an urgent need for more high quality seroprevalence and genetic data to represent HBV in Kenya to underpin improved HBV screening, treatment and prevention in order to support progress towards elimination targets.

12 September 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
WSWilliam H. K. Schilling
William H. K. Schilling
MMMavuto Mukaka
Mavuto Mukaka
JCJames Callery
James Callery
MLMartin J. Llewelyn
Martin J. Llewelyn
CCCintia V. Cruz
Cintia V. Cruz
OGon behalf of the COPCOV Collaborative Group
on behalf of the COPCOV Collaborative Group
Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation: In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration: ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947.

6 April 2024 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PYPaul Yonga
Paul Yonga
CPCéline Pulcini
Céline Pulcini
RSRobert Skov
Robert Skov
JPJose R. Paño-Pardo
Jose R. Paño-Pardo
JSJeroen Schouten
Jeroen Schouten

19 October 2022 in International Journal of Health Policy and Management
Verified
Journal Article
Open access
PDF file
LALukoye Atwoli
Lukoye Atwoli
GEGregory E. Erhabor
Gregory E. Erhabor
AGAiah A. Gbakima
Aiah A. Gbakima
AHAbraham Haileamlak
Abraham Haileamlak
JNJean-Marie Kayembe Ntumba
Jean-Marie Kayembe Ntumba
CZChris Zielinski
Chris Zielinski